Laura J.
Carter
*a,
Benny
Chefetz
b,
Ziad
Abdeen
cd and
Alistair B. A.
Boxall
e
aSchool of Geography, Faculty of Environment, University of Leeds, Leeds, LS2 9JT, UK. E-mail: l.j.carter@leeds.ac.uk
bDepartment of Soil and Water Sciences, Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot 7610001, Israel
cAl-Quds Public Health Society, Jerusalem, Palestine
dAl-Quds Nutrition and Health Research Institute, Al-Quds University, East Jerusalem, Palestine
eEnvironment Department, University of York, Heslington, York, YO10 5DD UK
First published on 1st April 2019
Use of reclaimed wastewater for agricultural irrigation is seen as an attractive option to meet agricultural water demands of a growing number of countries suffering from water scarcity. However, reclaimed wastewater contains pollutants which are introduced to the agro-environment during the irrigation process. While water reuse guidelines do consider selected classes of pollutants, they do not account for the presence of pollutants of emerging concern such as pharmaceuticals and the potential risks these may pose. Here we use source–pathway–receptor analysis (S–P–R) to develop a holistic framework for evaluating the impacts of pharmaceuticals, present in wastewater used for agricultural irrigation, on human and ecosystem health and evaluate the data availability for the framework components. The developed framework comprised of 34 processes and compartments but a good level of knowledge was available for only five of these suggesting that currently it is not possible to fully establish the impacts of pharmaceuticals in wastewater irrigation systems. To address this, work is urgently needed to understand the fate and transport of pharmaceuticals in arable soil systems and the effects of chronic low-level exposure to these substances on microbes, invertebrates, plants, wildlife and humans. In addition, research pertaining to the fate, uptake and effects of pharmaceutical mixtures and metabolites is lacking as well as data on bio-accessibility of pharmaceuticals after ingestion. Scientific advancements in the five areas prioritised in terms of future research are needed before we are able to fully quantify the agricultural and human health risks associated with reclaimed wastewater use.
Environmental significanceReclaimed wastewater irrigation presents a route by which pharmaceuticals can enter, and become, omnipresent in agricultural systems. Due to the biological potency of pharmaceuticals, uptake into receptors such as plants, livestock, and wildlife presents a risk to agricultural and human health. A holistic risk framework that considers the sources of pharmaceuticals and the pathways by which these chemicals can impact receptors has been proposed. Source–pathway–receptor analysis revealed that it is currently impossible to fully understand the risks of pharmaceuticals in agricultural systems due to a number of significant knowledge gaps. By identifying and prioritising these knowledge gaps, we envisage these findings will inform future regulatory and policy developments around the management of pharmaceutical contamination of reclaimed wastewater. |
Despite recent advances in technologies to treat wastewater, some pollutants of emerging concern such as pharmaceuticals and personal care products are not removed by wastewater treatment.9,10 These chemicals are frequently detected in both raw influent and treated effluents of wastewater treatment plants at concentrations ranging from ng L−1 to μg L−1.11,12 Concentrations of pharmaceuticals in wastewater vary across the globe. For example, the concentrations of a vast majority of antibiotics in effluents are generally higher in most Asian countries than those reported in European and North America10,13–15 with high concentrations explained by: high consumption and the fact that these compounds are readily available in these regions; and poor wastewater treatment technologies in some regions. In addition, different treatment technologies remove different chemicals to different extents thereby resulting in a range of concentrations in effluents. Concentrations of acetaminophen, for example, have been observed to range between below method detection limits to 62000 ng L−1 across wastewater treatment plants sampled in North America and Asia.12
An increasing number of studies have documented the presence of a wide range pharmaceuticals destined for land application.16–18 With the anticipated future increases in reclaimed wastewater reuse expected on a global scale (e.g. FAO report “Coping with water scarcity: an action framework for agriculture and food security”),19 the introduction of pharmaceuticals to agro-environments is also expected to increase. At the EU level it has been acknowledged that we need to develop minimum requirements to manage the human and environmental risks from reclaimed wastewater to irrigate crops (COM(2018)337).20 Classification of reclaimed wastewater destined for agricultural irrigation has therefore been proposed and this is based on monitoring for the presence of pathogens and physico-chemical constituents that may pose a risk to human and environmental health, and to environmental matrices (e.g. E. coli, biological oxygen demand, turbidity, and suspended solids).21 The proposed quality requirements for the EU are similar to the WHO Guidelines for the Safe Use of Wastewater, Excreta and Greywater22 and the Australian Guidelines for Water Recycling (Phase 1)23 when wastewater is used to irrigate of urban, recreational and open space, and agriculture and horticulture.
While, in some regions, the human health risks of pharmaceuticals are accounted for when wastewater is used for drinking water purposes (e.g. Australian Guidelines for Water Reuse: Augmentation of Drinking Water Supplies),24 there are currently no quality standards with regards to concentrations of pharmaceuticals in reclaimed wastewater used for irrigation. Given the current demand, and potential for future widespread use of reclaimed wastewater, it is essential we are able to adequately assess this risk. In order to contribute to the safe reuse of reclaimed wastewater in agriculture, policies and guidelines may need to be updated, and mitigation measures put in place to minimise environmental and human health impacts. There is therefore a need to develop new frameworks for determining the impacts of pharmaceuticals present in wastewater irrigation systems on agro-ecosystem and human health. In this paper, we therefore present a Source–Pathway–Receptor (S–P–R) analysis to establish a framework to describe how pharmaceuticals originating from reclaimed wastewater could impact on human health and the health of agricultural systems. We then assess the availability of knowledge, data, models and methods required to populate different components of the S–P–R diagram.
Number | Description | Existing knowledge | Knowledge gaps | Classification |
---|---|---|---|---|
A | Reclaimed wastewater | – Concentrations reported for many compounds33,35 | – Models often limited by availability of input data (e.g. usage data, WWTP removal data) | High |
– Good models to predict effluent concentrations38 | – Future scenarios (e.g. impact of climate change) | |||
– Presence of metabolites not well characterised | ||||
B | Agriculture water management systems | – Data available on what the systems are and where they are for select countries7 | – Limited information of chemical fate processes during piping (e.g. anaerobic conditions, biofilm processes, chlorination, reservoir storage, effects of temperature) | Moderate |
1 | Irrigation | – Good data on irrigation practices for select countries (location, volumes, frequency)121 | – Fate processes in drip irrigation systems | High |
C | Soil | – Experimental protocols exist to measure fate processes122 | – Predictive models are poor if input data is missing | Moderate |
– Measured data on fate (e.g. sorption, persistence) for many compounds51,52 | – Bioavailability (pore water concentrations) | |||
– Models exist to predict soil concentrations and chemical fate processes123 | – Monitoring data lacking for most compounds | |||
– Effect of reclaimed wastewater irrigation and hydroclimatic variables on soil fate processes | ||||
– Measured data on biotic and/or transformation in soil for many compounds | ||||
2 | Leaching to groundwater | – Limited experimental data for a few compounds63 | – No data for a majority of compounds | Moderate |
– Models are available124,125 | – Potential transformation processes during leaching | |||
E | Groundwater compartment | – Aquifer maps exist126,127 | – Limited information on chemical processes in the groundwater (including biotic and/or transformation) | Moderate |
– Some monitoring data63,66,128 | ||||
3 | Runoff to surface waters | – Good hydrological understanding for many countries129 | – Extreme events hard to predict (model scenarios not currently available) | High |
– Experimental monitoring ongoing61,130 | – Data on only a few compounds | |||
– Models are available131,132 | ||||
D | Surface water | – Monitoring data for many compounds33,35 | – Monitoring efforts focussed on Europe and N. America | Moderate |
– Data on in-stream processes are available for many compounds133,134 | – Exposure models not available for specific scenarios (e.g. limited wastewater treatment) | |||
– Measured data on biotic and/or transformation in soil for many compounds | ||||
4 and 5 | Abstraction of contaminated surface and groundwater | – Data on volumes, locations, frequency where practices exist135 | NA | High |
6 | Surface water to groundwater | NA | – Very limited understanding | Low |
7 | Use of reclaimed wastewater for aquaculture | – Known to be practiced in some areas136 | – Limited knowledge on aquaculture practices (e.g. where, volumes of water used) | Low |
8 | Uptake into microbes | NA | – Very limited understanding | Low |
J | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
– Knowledge of some effects on C and N transformation137,138 | – No information on mechanisms | Low |
– Limited molecular data139 | – No data on many compounds and key endpoints | |||
– Studies are on-going | – Effects of mixtures | |||
– Development and preservation of antimicrobial resistance | ||||
9 | Uptake into aquatic species | – Limited data for some species115,117 | – Models and measured data for invertebrates are lacking | Low |
– Some models are available (and account for ionisation)140–142 | – Lots of compounds have no data | |||
– Experimental protocols exist143 | ||||
K | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
– Some data available for acute and chronic effects (mostly fish) with a focus on effects of hormones on the reproductive system in fish144,145 | – Lots of compounds have no data | Moderate |
– Some models are available146,148 | – Influence of food chain transfer of chemicals | |||
– Effects of mixtures | ||||
– Antimicrobial resistance | ||||
10 | Uptake from soil into terrestrial plants | – Data available for some compounds in some plants and soils73–75 | – Models not designed for pharmaceuticals | Low |
– Models exist for uptake of organic compounds into plants149–151 | – Data lacking for most compounds at environmentally relevant concentrations (μg kg−1) | |||
– Limited number of plants studied | ||||
– Transformation products/in-plant metabolism | ||||
– Limited data on distribution in plant | ||||
– Multi-generational exposures | ||||
11 | Foliar plant uptake | – Data exists for a few compounds72 | – Models not available for pharmaceuticals | Low |
– Processes not understood | ||||
I | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
– Limited data on effects90,95 | – Limited data on most compounds at environmentally relevant concentrations | Low |
– Effects of transformation products | ||||
– Mechanisms not understood | ||||
– Long term effects on plant productivity (sub-lethal effects) | ||||
– Multi-generational exposures | ||||
12 | Consumption of drinking water | – Data on water consumption per capita and by livestock152,153 | NA | High |
G | ![]() ![]() ![]() ![]() ![]() |
– Calculated permissible uptake (e.g. ADI, AOELs, TTC)70,73 | – Long term, low level exposure | Moderate |
– Plasma therapeutic concentrations154 | – Mixtures | |||
– Health effects and side effects data (PK/PD)155 | – Sensitive sub-populations | |||
– Metabolism data/drug–drug interactions157 | – Metabolism at low concentrations | |||
– Mammalian toxicity data34,146 | ||||
– Occupational exposure157 | ||||
13 | Soil to terrestrial wildlife | – Limited information for some pharmaceuticals69,158 | – No data for most compounds | Low |
– Simple models available (via earthworm)109,159 | – Diets and routes of exposure poorly understood | |||
– Bioaccessibility | ||||
F | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
– Some data available for earthworms160 | – No data for most compounds | Low |
– Mammalian industry data available (rodents)34,146 | – Sub-therapeutic doses and effects | |||
– Bird toxicity data exists if it is a veterinary drug161 | – Long-term exposure and distribution in wildlife | |||
– Effects of mixtures and transformation products | ||||
14 | Microbe plant interactions | – Importance of microbes for plant systems162 | NA | Moderate |
– Information on soil microbiome100,163 | ||||
15 | Plant consumption by livestock | – General dietary information | – Dietary information for different species | Low |
– Some concentration data in forage crops164 | – Effects of crop processing | |||
– Bioaccessibility | ||||
H | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
– Some data exists if they are veterinary pharmaceuticals | – Sub-therapeutic doses | Low |
– Mammalian toxicity data available (rodents)34,146 | – Long-term exposure | |||
– Mixtures and transformation products | ||||
– Data lacking for most compounds | ||||
16 | Livestock to human | – Dietary information165 | – Cooking/processing/storage effects | Moderate |
– Dietary information for sub-populations is limited | ||||
– Bioaccessibility | ||||
17 | Plant consumption by humans | – General dietary information161,166 | – Dietary information for sub-populations | Moderate |
– Some concentration data103 | – Effects of cooking | |||
– Bioaccessibility | ||||
– Trade of food (source) | ||||
– Concentrations in edible part unknown for many crops | ||||
18 | Plant consumption by terrestrial wildlife | – Some data for birds and mammals167,168 | – Very little known for many species | Low |
– Bioaccessibility | ||||
19 | Microbes provide an ecosystem service to humans | – Importance known169 | – AMR transfer | Moderate |
20 | Consumption of fish by humans | – Limited monitoring data on levels in fish consumed by humans170,171 | – Dietary information for range of population (proportion of diet) | Low |
– Could be high risk for small parts of the population | ||||
21 | Consumption of fish by terrestrial wildlife | – Feeding patterns of wildlife167,168 | – Bioaccessibility and uptake | Low |
– Some models are available109 | – Species differences | |||
22 and 23 | Consumption of surface water by wildlife and livestock | – Feeding patterns of wildlife and livestock167,168 | – Not quantified for pharmaceuticals | Moderate |
– Good ecological data172 | ||||
24 | Consumption of wildlife by humans | – General dietary information for humans161,166 | – Not quantified for pharmaceuticals | Low |
– Bioaccessibility | ||||
– Could be high risk for small parts of the population |
![]() | ||
Fig. 2 Direct use of municipal wastewater for agricultural irrigation purposes (data collated from AQUASTAT publications).27 |
In an attempt to augment growing water demands, untreated wastewater is also used as a source of irrigation where wastewater infrastructure is lacking or where wastewater has undergone little to no treatment. For example in Mexico approximately 260
000 ha are irrigated with wastewater, most of which is untreated.2 There is an urgent need to identify where raw or partially treated wastewater is being used in agriculture to enable the risks to be properly assessed given that estimates indicate that at least 20 million hectares in 50 countries are irrigated with raw or partially wastewater.28,29
Through global monitoring campaigns we have a good understanding of the typical concentrations of pharmaceuticals in wastewater treatment plant (WWTP) effluent for some regions.30–32 According to a recent report by aus van der Beek,33 pharmaceuticals identified in treated wastewater comprise 28% of all global monitoring data with concentrations of a single pharmaceutical being reported up to 43900 μg L−1. However, of the approximately 1500 pharmaceuticals estimated to be currently in use,34 monitoring studies have only identified ∼550 active pharmaceutical ingredients in wastewater effluent (according to data reported on UBA Database: Pharmaceuticals in the Environment) (Table 2).33,35 In addition, monitoring studies have primarily centred on the quantification of pharmaceutical parent compounds with little effort made to identify the presence of metabolites and other transformation products.36,37 To add further complexity, for some geographic regions there is also limited or non-existent monitoring data on concentrations of pharmaceuticals in wastewater.33 If we do not have a clear picture of the quantities and types of pharmaceuticals and their transformation products in reclaimed wastewater this poses a major challenge when trying to assess the global risks associated with wastewater reuse in agriculture.
Therapeutic class | Rec. waste-water (A) | Soil (C) | Surface water (D) | Ground-water (E) | Wildlife (F) | People (G) | Livestock (H)a | Plants (I) | Soil fauna (J) | Aquatic species (K) | Examples of monitored drugs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
a Accumulation in livestock may also occur through veterinary use. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analgesic | ✓ | ✓ | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Acetaminophen | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antibiotic | ✓ | ✓ | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Ciprofloxacin, clarithromycin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antidepressant | ✓ | ✓ | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Fluoxetine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antidiabetic | ✓ | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Metformin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antiepileptic | ✓ | ✓ | ✓ | ✓ | — | ✓ | — | ✓ | — | ✓ | Carbamazepine, lamotrigine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antihypertensive | ✓ | ✓ | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Atenolol, metoprolol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-inflammatory | ✓ | ✓ | ✓ | ✓ | ✓ | — | — | ✓ | — | ✓ | Naproxen, diclofenac | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antineoplastic | ✓ | — | ✓ | ✓ | — | — | — | — | — | ✓ | Carboplatin, 5-fluorouracil | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antipsychotic | ✓ | — | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Diazepam, oxazepam | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antiviral | ✓ | — | ✓ | ✓ | — | — | — | — | — | — | Nevirapine, zidovudine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fibrates | ✓ | ✓ | ✓ | ✓ | — | — | — | ✓ | — | ✓ | Gemfibrozil, bezafibrate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Example references | 12, 32 and 173 | 47 and 48 | 33 and 35 | 62 and 174 | 113 | 103 | N/A | 6, 70, 75 and 104 | N/A | 115–117 | — |
Predictive modelling approaches, such as the multimedia box model SimpleTreat, offer a means of generating data on concentrations of pharmaceuticals in wastewater effluent by estimating chemical fate in activated sludge WWTPs.38 A recent evaluation found that, in general, SimpleTreat 4.0 was able to predict concentrations of pharmaceuticals in effluents to within a factor of 10 of measured concentrations.39 However, predictive approaches such as this typically require a large amounts of input data, for example information on pharmaceutical usage, sorption to sludge, and degree of chemical biodegradability. The availability of this data, which currently exists for a limited number of compounds, constrains model use in the first instance. On-going research to develop Quantitative Structure Property Relationships (QSPRs) to describe pharmaceutical sludge sorption and biodegradability40,41 and high-throughput approaches to identify transformation products42 will enable us to better model wastewater effluent concentrations in the future. In addition, models such as SimpleTreat are parametrised under the assumption that the WWTP is functioning correctly, and in some regions (e.g. Palestine), this is probably not the case, which will alter concentrations of pharmaceuticals in wastewater and thus the exposure to the agro-environment. We need to therefore understand the performance of different treatment technologies in different regions and further develop models to account for these differences.
In order to regulate peak demands as well as fluctuations in effluent flow, reclaimed wastewater is often stored in a reservoir and the influence of storage on chemical fate for a range of pharmaceuticals is largely unknown.43,44 However, published models that account for dissipation in water could be utilised to explore this further in combination with improved QSPRs for persistence in the water column and a greater understanding of reclaimed wastewater storage e.g. depth of reservoir, residence time in reservoir. In addition, research is needed to explore the chemical fate processes of pharmaceuticals during pipe flow to agricultural fields and during the drip irrigation process itself (Fig. 1; pathway 1). Recent research has established that biofilms can form around and within the drip irrigation devices,45 which have the potential to influence pharmaceutical retardation and/or degradation however very little is known about these processes.
Pollutants themselves can also alter soil microbial communities (as discussed under ‘Receptor’ section below) which have the potential to affect chemical degradability.52 This highlights the need to consider the composition of reclaimed wastewater and the alteration of the “reactivity” of soil microbial communities when evaluating the fate of pharmaceuticals after land application as these factors can have indirect effects on the fate of pollutants. In addition, long term reclaimed wastewater irrigation can lead to an alteration of soil properties (e.g. pH, heavy metals and nutrient content) which can in turn affect the fate of soil pollutants and this is something we know very little about.
Research has already highlighted the significant role soil properties play in the sorption and degradation of pharmaceuticals, and in particular ionisable pharmaceuticals (e.g. organic carbon content, cation exchange capacity, mineral content).51,52 With soil properties known to vary on a global scale (e.g. soil pH observed to range between 3.0 and 10.6 (ref. 56)), it is therefore imperative that future work to develop models to simulate fate processes in soils builds on recent research efforts such as the work of Droge and Goss57,58 and Franco et al.,41 to account for the significant role soil properties play in the fate of pharmaceuticals. In addition, fate modelling of pharmaceuticals should consider soil, hydrological and climatic factors that will alter in the future in response to a changing climate.
In addition to detecting pharmaceuticals in soils, monitoring campaigns have quantified the presence of pharmaceuticals in surface waters across the globe, however it is assumed this largely originates from the direct release of WWTP effluent.59,60 A small number of studies have demonstrated the mobilisation of pharmaceuticals following biosolids application to land25,61 however much less is known about the contribution of surface run-off to the contamination of water bodies after treated wastewater irrigation (pathway 3).18 Pharmaceuticals can also migrate from soils and contaminate groundwater supplies via leaching after reclaimed wastewater irrigation, with reported concentrations in groundwater typically being in the range of low ng L−1 (Fig. 1; pathway 2).53,62,63 However our understanding of the potential for the migration of pharmaceuticals to groundwater is primarily limited to a small number of soil column leaching experiments.64 For example, monitoring from the Penn State Living Filter suggests a clear indication of wastewater contribution to groundwater although concentrations were typically one to two orders of magnitude lower in comparison to WWTP effluent.63 This would suggest that soil has a limited capacity to act as a biogeochemical filter before the wastewater recharges underlying aquifers. More research is needed to understand the spatial–temporal factors influencing groundwater contamination including an evaluation of the potential pathway for pharmaceuticals to migrate to surface water from contaminated groundwater. Models have been developed to capture the transport of plant protection chemicals through the soil profile leaching into groundwater (e.g. FOCUS PEARL), but these models were not specifically parameterised for pharmaceuticals. Given the chemical similarity between plant protection products and pharmaceuticals (e.g. molecular weight, pKa within ionisable range) it is expected that these models will provide a good estimation as to the fate and transport of pharmaceuticals in soil. These models may however need to be refined to account for the effect of the reclaimed wastewater matrix on pharmaceutical transport. Studies on veterinary pharmaceuticals in soils have shown that these models under predict exposure, possibly due to colloid-facilitated transport of the pharmaceuticals.65
As well as reclaimed wastewater, surface and ground waters can also be used as a source of irrigation water thereby transferring these contaminants back into the soil environment. Abstraction of contaminated ground and surface water for irrigation is generally well characterised where such practices exist (Fig. 1; pathway 4 and 5), however our understanding of the transfer of pharmaceuticals from surface water to ground water via infiltration is limited to a select number of chemicals (Fig. 1; pathway 6).66 Heberer et al., demonstrated that whilst bank filtration can decrease the concentration of certain pharmaceuticals (dilution and/or removal) pharmaceutically active substances are still present in sampled ground waters at bank filtration sites.67 Similarly, the use of reclaimed wastewater to support aquaculture is known to be practiced68 although we have limited understanding of the specific locations and volumes of water used which presents a challenge with regards to quantifying the presence of pharmaceuticals in these systems (Fig. 1; pathway 7).
Similarly to the quantification of pharmaceuticals in soils there are several challenges associated with the extraction and detection of pharmaceuticals in plant samples including the identification of metabolites.77 Microbial driven processes can result in the formation of transformation products in soil,78 as well as their presence resulting from the direct application of wastewater containing metabolites formed in the patient or transformation products formed in the treatment process.48 Publications are also beginning to document in-plant metabolism/transformation of pharmaceuticals, particularly for the antiepileptic compound, carbamazepine.6,79–82 Data generated to date show that metabolites can be present in plants at levels similar to or greater than the parent compound.83 It is important to understand the transformation of a wider range of pharmaceuticals in soil-plant systems because the structure and polarity of metabolites can be drastically different from their parent compounds, and therefore it is expected that their fate, uptake and toxicity will be different.77
Models exist to predict transport and whole plant allocation of organic chemicals, including uptake from soil and following foliar application.84–87 However, often these models, which are either simple correlations with compound properties or more complex compartmental models, do often not account for the complexity of the factors and processes determining pharmaceutical uptake, including chemical speciation, in-plant metabolism and differences in plant physiology. Given the widespread use of reclaimed wastewater, containing a range of pharmaceuticals to irrigate a globally diverse set of crops, it is impossible to gather experimental data for all these scenarios. It is therefore essential that new models, that cover a range of plant traits and exposure scenarios, are developed to predict the uptake of pharmaceuticals into plants, so we can adequately assess the risks arising from this accumulation. The development of models for individual compound classes and for separate plant species may therefore represent a promising approach for future model development.88
Due to the biological potency of pharmaceuticals and their metabolites, accumulation of these chemicals in plants presents a risk to the health of the plant directly as well as to the organisms that feed on the plant material, including humans and terrestrial wildlife. For example, exposure of plants to antibiotics has been shown to affect plant biomass.89–91 In addition to visible whole-plant morphological symptoms, pharmaceuticals have also been shown to have the potential to affect in-plant homeostasis, such as changes in phytohormones, cellular metabolism, nutrient uptake and signaling without phenotypic change.92–95 These changes at the subcellular scale and molecular level may be considered as the underlying mechanisms for the long-term visual phytotoxic responses, e.g., plant biomass effects. It is unsurprising that pharmaceutical induced effects have been observed given that these chemicals are designed to interact with specific molecular targets in humans and these targets have orthologs that are conserved in other species e.g. 20–25% the drug targets in humans had predicted orthologs in plants.96 Specifically, common receptors have been identified in plants for a number of antibiotics affecting plant physiological responses (e.g. chloroplast replication).97 We need to understand the mechanisms driving these effect responses, whether they are a direct interaction between the chemical and a receptor or an indirect effect of the chemical affecting soil microbial homeostasis which is in turn affecting plant health (pathway 14; see below for more detail on soil microbial communities).
Research regarding potential effects in non-target terrestrial wildlife remains scarce,111,112 with minimal data on long term exposure and distribution in higher vertebrates as well as the effects of pharmaceutical mixtures and transformation products.69 Given that the decline of the Asian vulture population has been attributable to exposure of a commonly prescribed non-steroidal anti-inflammatory, diclofenac,113 and the current lack of exposure and effects data in this area, research efforts are needed to evaluate pharmaceutical contaminants in terrestrial wildlife systems. Specifically, we need to advance our understanding of biomagnification and the effects of pharmaceuticals in food webs.
Of the 34 individual components of the S–P–R diagram we only have high level of understanding of 5 of these (Table 1). We have a greater understanding of the sources of pharmaceuticals in reclaimed wastewater and irrigation practices whereas we only have a low moderate understanding of the processes by which pharmaceuticals move between sources and are taken up by receptors. As the fate and behaviour of most pharmaceuticals entering our agriculture systems remains poorly characterized, our conception and understanding of the risks posed to receptors is equally constrained.
Future research efforts should therefore seek to address five main areas over the next 15–20 years (Fig. 3):
![]() | ||
Fig. 3 Possible time lines and strategy for prioritised research areas, to better understand the fate, uptake and effects of wastewater derived pharmaceuticals in agro-ecosystems. |
– Use non-target screening approaches to explore the formation of biologically active metabolites (and conjugates) to complement targeted analysis based on identified transformation pathways of pharmaceuticals known to be persistent in agro-ecosystems.
– Account for the varying performance of different WWTP technologies in different regions and to provide a greater understanding on the use of raw or partially treated wastewater (including water used in aquaculture) for irrigation where sewage connectivity is limited or non-existent.
– Understand how future environmental change (e.g. increased temperature, drought) and agricultural developments (e.g. increased global food demand) will alter the environmental exposure of pharmaceuticals.
– Investigate the uptake of pharmaceuticals by receptors after low-level chronic exposure and as well in response to mixture exposures.
– Determine the formation of pharmaceutical transformation products in receptors and identify metabolism pathways to help assist with predictive model development (see below).
– Identify key factors which alter the uptake, accumulation and bioaccessibility of pharmaceuticals in receptors accounting for species traits and exposure medium properties.
– Account for geographical and species variations in diets, food sourcing and exposure concentrations of pharmaceuticals.
– Investigate the suitability of analogous approaches to those adopted for predicting the effects of pharmaceuticals in the aquatic environment (e.g. chemical read-across).
– Develop thresholds to evaluate the human health risks from consuming produce containing pharmaceutical residues, considering chemical mixtures (i.e. likelihood of contraindications) and populations deemed most at risk (e.g. elderly, children).
Use of reclaimed wastewater irrigation results in the contamination of a number of environmental compartments, each of which can act as reservoirs of pharmaceuticals. These chemicals have the potential to accumulate in a variety of receptors including terrestrial wildlife, livestock, terrestrial plants, aquatic species, soil microbial community and humans, posing a range of potential health and environmental challenges. This risk may be greatest in low to middle income countries where wastewater treatment technologies are limited or often non-existent leading to an increased use of semi treated or non-treated wastewater.
A number of broad knowledge gaps were identified, most notably that more research is needed to consider the effect of metabolites on the various pathways and receptors highlighted in Fig. 1. In addition, research pertaining to the effect and fate of pharmaceutical mixtures are lacking as well as data on bio accessibility of pharmaceuticals after ingestion by humans, wildlife and livestock. Ultimately, use of reclaimed wastewater will require a trade-off between the economic benefits and ability to meet growing populations' food demands and the environmental and human health risks associated with using reclaimed wastewater as an irrigation source. More research is needed to fully understand these risks to ensure agricultural sustainability to guide future water reuse policies.
This journal is © The Royal Society of Chemistry 2019 |